Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance
- PMID: 11787527
- DOI: 10.1053/bbmt.2001.v7.pm11787527
Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance
Abstract
Background: Successful transplantation of solid organs relies on long-term immunosuppression for the prevention of graft rejection. Donor-specific tolerance without the need for continuous immunosuppression can be observed after allogeneic BMT. However, its routine use for tolerance induction has been precluded so far by the high conditioning-related toxicity of standard BMT regimens. Our laboratory has recently established a cyclophosphamide (CTX) plus thymic irradiation (TI)-based nonmyeloablative conditioning protocol for the treatment of hematologic malignancies. We have recently described the successful clinical application of this approach for the induction of donor-specific tolerance in a patient receiving a living-related kidney transplant, which resulted in graft acceptance without long-term immunosuppression. The aim of this study was to evaluate the induction and maintenance of host-versus-graft tolerance following this CTX-plus-TI-based regimen in a mouse model.
Methods: Induction of mixed hematopoietic chimerism and development of donor-specific tolerance following the CTX-based nonmyeloablative conditioning regimen (200 mg/kg CTX, in vivo T-cell depletion [anti-CD4 monoclonal antibody (MoAb) GK1.5 and anti-CD8 MoAb 2.43], and 7 Gy TI) was studied in the fully major histocompatibility complex (MHC)-mismatched B10.A (H2a)-->B6 (H2b) strain combination.
Results: The conditioning regimen allowed allogeneic bone marrow engraftment and persistent (>30 weeks) mixed lymphohematopoietic chimerism in almost all recipients. TI was essential to allow engraftment and development of tolerance, which was evident in all lasting chimeras. Compared to animals receiving a similar TBI-based conditioning regimen, overall levels of chimerism were significantly lower in the CTX-plus-TI-conditioned animals. However, donor-specific tolerance in vitro and in vivo was evident in CTX-plus-TI-conditioned chimeras. Tolerance was associated with the presence of donor-type MHC class II+ cells in the thymus and deletion of donor-reactive cells, as determined by Mtv-8 and Mtv-9 superantigen-mediated deletion of Vbeta11+ and Vbeta5/1.2+ T cells.
Conclusion: Engraftment, long-term chimerism, and induction of donor-specific tolerance can be achieved using a nonmyeloablative CTX-based conditioning regimen in fully MHC-mismatched BMT recipients without the induction of GVHD.
Similar articles
-
Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen.Biol Blood Marrow Transplant. 1999;5(3):133-43. doi: 10.1053/bbmt.1999.v5.pm10392959. Biol Blood Marrow Transplant. 1999. PMID: 10392959
-
Blockade of the CD40/CD154 pathway enhances T-cell-depleted allogeneic bone marrow engraftment under nonmyeloablative and irradiation-free conditioning therapy.Transplantation. 2003 Jul 15;76(1):216-24. doi: 10.1097/01.TP.0000069602.30162.A1. Transplantation. 2003. PMID: 12865813
-
Hematopoietic cell transplantation for the induction of allo- and xenotolerance.Clin Transplant. 1996 Aug;10(4):357-63. Clin Transplant. 1996. PMID: 8884109 Review.
-
A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.J Immunol. 1995 Nov 1;155(9):4179-88. J Immunol. 1995. PMID: 7594573
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
Cited by
-
A new anti-mesothelin antibody targets selectively the membrane-associated form.MAbs. 2017 Apr;9(3):567-577. doi: 10.1080/19420862.2017.1288770. MAbs. 2017. PMID: 28353419 Free PMC article.
-
Specific immunosuppression by mixed chimerism with bone marrow transplantation after Staphylococcal Enterotoxin B pretreatment could prolong corneal allograft survival in mice.Mol Vis. 2012;18:974-82. Epub 2012 Apr 18. Mol Vis. 2012. PMID: 22550390 Free PMC article.
-
Transplantation tolerance through mixed chimerism.Nat Rev Nephrol. 2010 Oct;6(10):594-605. doi: 10.1038/nrneph.2010.110. Epub 2010 Aug 31. Nat Rev Nephrol. 2010. PMID: 20808286 Review.
-
Long-term follow-up of recipients of combined human leukocyte antigen-matched bone marrow and kidney transplantation for multiple myeloma with end-stage renal disease.Transplantation. 2011 Mar 27;91(6):672-6. doi: 10.1097/TP.0b013e31820a3068. Transplantation. 2011. PMID: 21217460 Free PMC article.
-
Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions.Blood. 2006 Sep 15;108(6):2106-13. doi: 10.1182/blood-2006-03-007427. Epub 2006 Jun 6. Blood. 2006. PMID: 16757687 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials